 Study parameters to evaluate short term safety and tolerability will be vital signs heart frequency, blood pressure, cardiac ischemia before and until 15 minutes after administration. Serious Adverse Events will be recorded on the ICU up to 7 days or until discharge from the ICU. For evaluation of the pharmacokinetics profile of 2-IB, 9 plasma samples will be analysed. Secondary parameters: Biochemical markers Neuron specific Enolase and s100b at 24h and 48h after start of study drug, occurrence of SAEs until 30 days after OHCA including death, long term term efficacy as determined by the Cerebral Performance Category CPC, the Informant Questionnaire on Cognitive Decline in the Elderly IQCODE or the Telephone Interview Cognitive Status TICS scale at 30 days after OHCA. 